Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2005-04-19
2005-04-19
Kunz, Gary (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S185100, C424S198100, C514S002600, C514S012200, C530S350000, C530S351000, C530S399000
Reexamination Certificate
active
06881401
ABSTRACT:
The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
REFERENCES:
patent: 6297367 (2001-10-01), Tribouley
patent: 869180 (1998-07-01), None
patent: 921194 (1999-06-01), None
patent: WO9733902 (1997-09-01), None
patent: WO9818921 (1998-05-01), None
patent: WO9827114 (1998-06-01), None
patent: WO9855620 (1998-12-01), None
patent: WO9855621 (1998-12-01), None
patent: WO9911791 (1999-03-01), None
patent: WO9912964 (1999-03-01), None
patent: WO9933980 (1999-07-01), None
patent: WO0026244 (2000-05-01), None
patent: WO0039295 (2000-07-01), None
patent: WO0040716 (2000-07-01), None
patent: WO0043032 (2000-07-01), None
patent: WO0045836 (2000-08-01), None
patent: WO0047740 (2000-08-01), None
patent: WO0050597 (2000-08-01), None
patent: WO0060079 (2000-10-01), None
patent: WO0067034 (2000-11-01), None
patent: WO0068378 (2000-11-01), None
patent: WO0077256 (2000-12-01), None
patent: WO0140466 (2001-06-01), None
Hammarstrom et al. Selective IgA deficiency (SlgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 120 225-231, 2000.*
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.*
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.*
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.*
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.*
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.*
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.*
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.*
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.*
Farrah et al., GenBank Accession No. AF186114, Jan. 13, 2000.
Ferguson et al., Human Molecular Genetics 6:1589-1594.
Fujiwara et al., GenBank Accession No. D79690, Feb. 9, 1996.
Hillier et al., GenBank Accession No. AA166695, Nov. 9, 1997.
Hillier et al., GenBank Accession No. AA682496, Dec. 19, 1997.
Hillier et al., GenBank Accession No. R16882, Apr. 14, 1995.
Hillier et al., GenBank Accession No. R16934, Apr. 14, 1995.
Hillier et al., GenBank Accession No. T87299, Mar. 17, 1995.
Marra et al., GenBank Accession No. AA422749, Oct. 16, 1997.
Marra et al., GenBank Accession No. AI182472, Oct. 8, 1998.
Myers., GenBank Accession No. G30081, Oct. 5, 1996.
NCI-CGAP., GenBank Accession No. AA906714, Jun. 9, 1998.
Zhang et al., GenBank Accession No. AF134715, Mar. 28, 2000.
Baumgarth,Nicole, Secreted IgM versus BlyS in germinal center formation, Nature Immunology, (2000) 1:179.
Cyster, Jason G., Marginal zone B cells may steal the limelight as the roles of Pyk-2 and BlyS begin to be elucidated. Pyk-2 deficiency leads to their loss whereas signaling via the BlyS receptor may augment their function, Nature Immunology, (2000) 1:9-10.
Do et al., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, J. Exp. Med., (2000) 192:953-964.
Gross et al.; TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, (2000) 404:995-999.
Hatzoglou et al., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.
Hu et al., Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily, Genomics, 62:1023-107 (1999).
Kanakaraj et al., BlyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-κ and Elf-1, Cytokine (2001) 13:25-31.
Khare et al., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, PNAS, (2000) 97:3370-3375.
Laabi et al., Lymphocyte Survival—Ignorance is BlyS, Science Magazine, (2001) 289:883.
Mackay et al., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, J. Exp. Med., (1999) 190:1697-1710.
Marsters, et al., Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI, Current Biology, (2000) 10:785-788.
Moore et al., BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285: 285:260-263.
Nardelli et al., Synthesis and release of B-lymphocyte stimulator from myeloid cells, Immunobiology, (2001) 97:198-204.
Parry et al., Pharmacokinetics and Immunological Effects of Exogenously administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice, The Journal of Pharmacology and Experimental Therapies, (2001) 296:396-404.
Schneider et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, J. Exp. Med., (1999) 189:1747-1756.
Shu et al., TALL-1 is a novel member of the TNF Family that is Down-regulated by Mitogens, J. Leukoc. Biol., 65:680-683 (1999).
Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, J. Exp. Med., (2000) 192:129-135.
Wu et al., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receiptor for TNF Family Members APRIL and BlyS, The Journal of Biological Chemistry (2000) 275:34578-34585.
Xia et al., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, J. Exp. Med., (2000) 192:137-143.
Yan et al., Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity, Nature Immunology, (2000) 1:37-41.
Yu et al., APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity, (2000) 1:252-256.
Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10.
U.S. Appl. No. 08/984,396, SmithKline Beecham
U.S. Appl. No. 60/033,601, Schering
U.S. Appl. No. 60/041,797, SmithKline Beecham
U.S. Appl. No. 60/048,776, Regeneron
U.S. Appl. No. 60/058,786, Biogen
U.S. Appl. No. 60/066,386, Regeneron
U.S. Appl. No. 60/066,577, Eli Lilly
U.S. Appl. No. 60/068,959, Chiron
U.S. Appl. No. 60/096,173, Eli Lilly
U.S. Appl. No. 60/106,976, U.S. Government -DHHS
U.S. Appl. No. 60/117,169, Biogen
Ebner Reinhard
Ni Jian
Rosen Craig A.
Yu Guo-Liang
Bunner Bridget E.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Kunz Gary
LandOfFree
Methods of treatment of immune system related disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment of immune system related disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of immune system related disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3390171